Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 4/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14521614 | 1.00 | CA14 (0.48) | CA14MEN1KMT2ABIRC2LMNA | |
| SCHEMBL13912228 | 1.00 | CA14 (0.48) | CA14MEN1KMT2ABIRC2LMNA | |
| SCHEMBL21488050 | 0.81 | METAP2 (0.33) | CA14MEN1KMT2ABIRC2LMNA | |
| SCHEMBL13645688 | 0.81 | CA14 (0.45) | CA14MEN1KMT2ABIRC2LMNA | |
| SCHEMBL20377521 | 0.81 | DPP4 (0.48) | CA14MEN1KMT2ABIRC2LMNA | |
| SCHEMBL13511539 | 0.81 | DPP4 (0.48) | CA14MEN1KMT2ABIRC2LMNA | |
| SCHEMBL12890766 | 0.81 | CA14 (0.45) | CA14MEN1KMT2ABIRC2LMNA | |
| SCHEMBL16000773 | 0.81 | DPP4 (0.48) | CA14MEN1KMT2ABIRC2LMNA | |
| SCHEMBL9947502 | 0.81 | CA14 (0.45) | CA14MEN1KMT2ABIRC2LMNA | |
| SCHEMBL12890756 | 0.81 | CA14 (0.45) | CA14MEN1KMT2ABIRC2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4215530-A1 | ISOXAZOLINE COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTS | FMC Corporation (US) | 2023-07-26 | — | — | EP | disclosed |
| US-20230150989-A1 | HERBICIDAL MALONAMIDES | BASF SE (DE) | 2023-05-18 | — | — | US | disclosed |
| US-20210309652-A1 | ISOXAZOLINE COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTS | FMC CORPORATION | 2021-10-07 | — | — | US | disclosed |
| WO-2020018610-A1 | ISOXAZOLINE COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTS | FMC CORPORATION (US) | 2020-01-23 | — | — | WO | disclosed |
| US-7507820-B2 | Diazaphosphacycles | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2009-03-24 | — | — | US | disclosed |
| US-7169919-B2 | Process for preparing lipid II | ELI LILLY AND COMPANY (US) | 2007-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210309652-A1 | ISOXAZOLINE COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTS | PRDX1, CYP4X1, RDX | CA14 4429/4885MEN1 3140/4885KMT2A 1882/4885 |
| US-20230150989-A1 | HERBICIDAL MALONAMIDES | DDT, DHRS9, CA9 | CA14 646/4885MEN1 2853/4885KMT2A 1533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.